Skip to main
OMER
OMER logo

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corporation is positioned positively due to the promising results of its drug candidate, narsoplimab, demonstrating statistically significant survival advantages in patients with transplant-associated thrombotic microangiopathy (TA-TMA), which enhances the clinical foundation of its therapy amid competitive market dynamics. Additionally, the company has shown favorable Phase 2 results for zaltenibart in treating paroxysmal nocturnal hemoglobinuria, indicating its potential for safety, tolerability, and superiority over existing alternative pathway inhibitors, thus opening avenues for considerable market potential. The successful developments in both therapeutic areas underscore Omeros's ability to navigate the clinical landscape effectively, presenting a robust outlook for the company's financial trajectory as it continues to advance its innovative portfolio.

Bears say

Omeros Corp has faced significant operating losses, with no expectation of achieving profitability in the foreseeable future, primarily due to the high costs associated with research and development for its drug candidate, narsoplimab. The company operates in niche disease markets, with low patient prevalence, which may hinder its commercial viability despite a pressing unmet medical need in conditions like thrombotic microangiopathy. Additionally, there remains considerable uncertainty surrounding the FDA approval of narsoplimab, attributed to an unconventional development trajectory, limited clinical trial data, and a prolonged timeframe since the last review without new supporting evidence.

Omeros (OMER) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.